Company: SNY
Filing Date: 2025-10-27
Form Type: 424B5
Source: 0001193125-25-250786
Chunk: 69

Company: Sanofi
Filing Date: 2025-10-27
Form: 424B5
Chunk 69
---
 to the Annual Report on Form 20-F for the year ended December 31, 2024 have been so incorporated in reliance on the report
(which contains an explanatory paragraph on the fact that ERNST & YOUNG et Autres was not engaged to audit, review, or apply any procedures to the adjustments to retrospectively reflect the classification as discontinued operations of
Opella described in Note D.1.1.2 and to the recast of the segment information described in Note D.35, and, accordingly ERNST & YOUNG et Autres does not express an opinion or any other form of assurance about whether such adjustments
are appropriate and have been properly applied; those adjustments were audited by PricewaterhouseCoopers Audit in 2024; in the opinion of PricewaterhouseCoopers Audit, such adjustments are appropriate and have been properly applied) of
PricewaterhouseCoopers Audit and Ernst & Young et Autres, independent registered public accounting firms, given on the authority of said firms as experts in auditing and accounting.

S-51

PROSPECTUS

Sanofi

### DEBT SECURITIES
We may offer and sell debt securities from time to time. Each time we sell any of the debt securities described in this prospectus, we will
provide one or more supplements to this prospectus that will contain specific information about those debt securities and the offering to which it relates. You should read this prospectus and any applicable prospectus supplement(s) carefully before
you invest.

We may sell these debt securities to or through underwriters and also to other purchasers or through agents. The names of any
underwriters or agents will be stated in an accompanying prospectus supplement.

Investing in these debt securities involves certain risks. See “ Risk Factors” beginning on page 7.

Neither the U.S. Securities and Exchange Commission (the “SEC” or “Commission”) nor any other regulatory body has approved or disapproved of these debt securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

Prospectus dated April 4, 2024

TABLE OF CONTENTS

|                                                           |     | Page |    |
| ABOUT THIS PROSPECTUS                                     |     |      |  1 |
| CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS |     |      |  1 |
| WHERE YOU CAN FIND MORE INFORMATION                       |     |      |  2 |
| INCORPOR